BIBF 1120

• CAT Number: I004473
• CAS Number: 656247-17-5
• Molecular Formula: C31H33N5O4
• Molecular Weight: 539.6
• Purity: ≥95%
• Target: PDGFR
• Solubility: 10 mM in DMSO
• Storage: -20°C
• InChI: InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-
• InChIKey: XZXHXSATPCNXJR-ZIADKAODSA-N
• SMILES: O=C1NC2=CC(C(OC)=O)=CC=C2/C1=C(C3=CC=CC=C3)/NC4=CC=C(N(C(CN5CCN(C)CC5)=O)C)C=C4

Nintedanib(CAT: I004473), also known as BIBF 1120, is a potent inhibitor of multiple angiokinase receptors. It targets and inhibits the activity of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, fibroblast growth factor receptors (FGFR) 1, 2, and 3, and platelet-derived growth factor receptors (PDGFR) α and β. By inhibiting these receptors, nintedanib disrupts signaling pathways involved in angiogenesis, the formation of new blood vessels. This mechanism of action makes nintedanib useful in the treatment of certain types of cancer, including non-small cell lung cancer and idiopathic pulmonary fibrosis, as well as other fibrotic and neovascular diseases.

Reference

1: Gori B, Ricciardi S, Fulvi A, Intagliata S, Del Signore E, de Marinis F. New
antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120)
and beyond. Ther Clin Risk Manag. 2011;7:429-40. doi: 10.2147/TCRM.S22079. Epub
2011 Nov 17. PubMed PMID: 22241943; PubMed Central PMCID: PMC3253753.

2: Reck M. BIBF 1120 for the treatment of non-small cell lung cancer. Expert Opin
Investig Drugs. 2010 Jun;19(6):789-94. doi: 10.1517/13543784.2010.488220. Review.
PubMed PMID: 20465363.

3: du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt
VL, Harter P. A phase I open-label dose-escalation study of oral BIBF 1120
combined with standard paclitaxel and carboplatin in patients with advanced
gynecological malignancies. Ann Oncol. 2010 Feb;21(2):370-5. doi:
10.1093/annonc/mdp506. Epub 2009 Nov 4. PubMed PMID: 19889612.

4: Kropff M, Kienast J, Bisping G, Berdel WE, Gaschler-Markefski B, Stopfer P,
Stefanic M, Munzert G. An open-label dose-escalation study of BIBF 1120 in
patients with relapsed or refractory multiple myeloma. Anticancer Res. 2009
Oct;29(10):4233-8. PubMed PMID: 19846979.

5: Miyazaki K, Collins DJ, Walker-Samuel S, Taylor JN, Padhani AR, Leach MO, Koh
DM. Quantitative mapping of hepatic perfusion index using MR imaging: a potential
reproducible tool for assessing tumour response to treatment with the
antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur
Radiol. 2008 Jul;18(7):1414-21. doi: 10.1007/s00330-008-0898-9. Epub 2008 Mar 20.
PubMed PMID: 18351351.

6: Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U,
Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. BIBF 1120:
triple angiokinase inhibitor with sustained receptor blockade and good antitumor
efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi:
10.1158/0008-5472.CAN-07-6307. PubMed PMID: 18559524.